Lymphomatoid papulosis progressing to immunoblastic lymphoma

Tucker, William F.; Leonard, J.N.; Smith, N.P.; Coulter, Carmel; Woods, Brian; Clayton, Roger

doi:10.1111/j.1365-2230.1984.tb00782.x

Cited by 17 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pityriasis lichenoides et varioliformis acuta (PLEVA) and lymphomatoid papulosis (LyP) are benign self‐healing cutaneous eruptions that may be clinically and histologically similar. Clinically it is important to distinguish PLEVA and LyP because LyP but not PLEVA is reported to be associated with malignant lymphoma in 5% to 20% of cases 1–6 . LyP is now considered to belong to the spectrum of CD30+ cutaneous lymphoproliferative disorders, which also include cutaneous anaplastic large cell lymphomas and CD30+ pleomorphic lymphomas 7…”

mentioning

confidence: 99%

Expression of cutaneous lymphocyte‐associated antigen and TIA‐1 by lymphocytes in pityriasis lichenoides et varioliformis acuta and lymphomatoid papulosis: immunohistochemical study

Jang

Choi

2001

J Cutan Pathol

View full text Add to dashboard Cite

Immunohistochemical stains for CD8, CD30, CD79 and CLA may be valuable tools in the differential diagnosis between PLEVA and LyP. TIA-1 was negative in LyP, which means cytotoxic cells may not be implicated in the pathogenesis of LyP. It was a contradictory result to the previous results. The absence of EBV in PLEVA and LyP suggests that this virus may not be operative in the pathogenesis of these diseases. These results suggest that LyP and PLEVA are separate disorders, thus accounting for their variable prognosis.

show abstract

mentioning

confidence: 99%

Expression of cutaneous lymphocyte‐associated antigen and TIA‐1 by lymphocytes in pityriasis lichenoides et varioliformis acuta and lymphomatoid papulosis: immunohistochemical study

Jang

Choi

2001

J Cutan Pathol

View full text Add to dashboard Cite

show abstract

“…The latter may be defined by lesions of larger size that do not regress, by the presence of nodal disease, or the t(2,5) translocation [7]. Other lymphomas that may follow or coexist with LyP lesions are mycosis fungoides and Hodgkin’s disease [6]and less frequently peripheral T cell lymphomas or immunoblastic lymphomas [8, 9, 10, 11, 12, 13, 14, 15]. …”

Section: Introductionmentioning

confidence: 99%

Bexarotene Is a New Treatment Option for Lymphomatoid Papulosis

Krathen

Ward

Duvic³

2003

Dermatology

View full text Add to dashboard Cite

Background: Lymphomatoid papulosis (LyP) is a clonal T cell proliferation with large cell histology, a chronic course, and an increased risk of lymphoma. Bexarotene (Targretin^®) is an RXR-selective retinoid (rexinoid) approved for the cutaneous manifestations of cutaneous T cell lymphoma. Objective: To determine whether bexarotene is effective in treating LyP. Methods: Ten patients with chronic and symptomatic LyP were prospectively treated with oral (n = 3) or topical gel (n = 7) formulations of bexarotene. Results: A favorable response to bexarotene treatment with decreased numbers or duration of lesions was seen in all with objective responses in 8 patients. Conclusions: Bexarotene may be an effective palliative treatment for LyP, warranting further controlled studies.

show abstract

Lymphomatoid Papulosis Associated With Plaque-Stage and Granulomatous Mycosis Fungoides

Kardashian¹

1985

Arch Dermatol

View full text Add to dashboard Cite

Lymphomatoid papulosis progressing to immunoblastic lymphoma

Cited by 17 publications

References 12 publications

Expression of cutaneous lymphocyte‐associated antigen and TIA‐1 by lymphocytes in pityriasis lichenoides et varioliformis acuta and lymphomatoid papulosis: immunohistochemical study

Expression of cutaneous lymphocyte‐associated antigen and TIA‐1 by lymphocytes in pityriasis lichenoides et varioliformis acuta and lymphomatoid papulosis: immunohistochemical study

Bexarotene Is a New Treatment Option for Lymphomatoid Papulosis

Lymphomatoid Papulosis Associated With Plaque-Stage and Granulomatous Mycosis Fungoides

Contact Info

Product

Resources

About